Guanghui Gao

Dr. Guanghui Gao


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2023 in Experimental Hematology & Oncology
Verified
Journal Article
Open access
PDF file
FZFei Zhou
Fei Zhou
JSJianguo Sun
Jianguo Sun
LYLingyun Ye
Lingyun Ye
TJTao Jiang
Tao Jiang
WLWei Li
Wei Li
GGGuanghui Gao
Guanghui Gao
Background: Fibronectin, an extracellular matrix protein, has been reported to be associated with heterogeneous cancer stemness, angiogenesis and progression in multiple cancer types. However, the roles and the underlying mechanism of fibronectin on the progression NSCLC need to be further elucidated. Methods: Public dataset such as Kaplan-Meier Plotter was used to determine the prognostic significance of genes. The correlation of different protein expression in clinical and xenograft tissues was tested by immunohistochemistry experiment. Both in vitro and in vivo experiments were performed to determine the role of fibronectin on the tumor growth, metastasis, and angiogenesis in NSCLC. The activation of key signaling pathway under fibronectin was examined by WB assay. RNA-seq was applicated to screening the target gene of fibronectin. Rescue experiment was performed to confirm the role of target gene in fibronectin-mediated function in NSCLC. Finally, luciferase and CHIP assays were used to elucidate the mechanism by which fibronectin regulated the target gene. Results: Our results revealed that fibronectin was up-regulated in cancer tissues compared with the normal ones in NSCLC patients. Dish- coated fibronectin enhanced the tumor growth, metastasis, and angiogenesis of NSCLC in vitro and in vivo by promoting EMT and maintaining stemness of NSCLC cells. As expected, fibronectin activated FAK and its downstream MAPK/ERK signaling pathway. WISP3 was screened as a potential target gene of fibronectin. Interestingly, WISP3 effectively activated Wnt signaling pathway, and knockdown of WISP3 effectively blocked the influence of fibronectin on the migration, invasion and vascular structure formation potential of NSCLC cells. Our data also manifested that fibronectin elevated the transcription of WISP3 gene by promoting the binding of HIF-1α to the promoter region of WISP3 in NSCLC cells. Conclusions: Our findings sketched the outline of the route for fibronectin exert its role in NSCLC, in which fibronectin activated downstream FAK and MAPK/ERK signaling pathways, and mediated the accumulation of HIF-1α. Then, HIF-1α enabled the transcription of WISP3, and subsequently promoted the activation of Wnt signaling pathway, and finally enhanced the tumor growth, metastasis, and angiogenesis in NSCLC.

3 December 2025 in Frontiers in Medicine
Verified
Journal Article
Open access
LYLingyun Ye
Lingyun Ye
XHXinnan Hu
Xinnan Hu
SCShen Chen
Shen Chen
HWHai Wang
Hai Wang
JLJuanjuan Li
Juanjuan Li
XSXiao Song
Xiao Song
Background: Many studies have found that exosomes have numerous advantages in the early diagnosis of tumors. We detected and analyzed plasma exosomes from lung cancer patients to identify potential biomarkers that could predict brain metastasis. Method: The total RNA of plasma exosomes of advanced lung cancer patients was extracted and sequenced. The BLAST software was used to align the predicted target gene sequence against the GO and KEGG databases, thereby acquiring annotation details for the target genes. The selected exosomal miRNAs and short-chain fatty acids were subjected to diagnostic performance validation analysis. Results: Exosomal miR-223-3p, miR-27a-3p, and miR-27b-3p were significantly increased in the plasma exosomes of lung cancer patients with brain metastasis. The concentrations of isobutyric acid (IBA), valeric acid (VA), isovaleric acid (IVA), and acetic acid (AA) were markedly elevated in the plasma exosomes of lung cancer patients with brain metastasis. Spearman correlation analysis revealed that both miR-27a-3p and miR-27b-3p had significant associations with IVA and VA. A multi-biomarker model combining the selected exosomal miRNAs with metabolic molecules could improve the diagnostic performance with an AUC of 0.927. Conclusion: Plasma exosomal miR-223-3p, miR-27a-3p, miR-27b-3p, and IBA, IVA, VA, and AA in advanced patients are closely associated with brain metastasis and have the potential to act as biomarkers for predicting brain metastasis in lung cancer patients.

24 June 2025 in Biochemical Pharmacology
Verified
Journal Article
Open access
XZXiaoshen Zhang
Xiaoshen Zhang
TJTao Jiang
Tao Jiang
LYLingyun Ye
Lingyun Ye
JSJianguo Sun
Jianguo Sun
LWLei Wang
Lei Wang
GGGuanghui Gao
Guanghui Gao
Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancer cases, posing a major health burden. Our prior work indicated fibronectin promotes NSCLC angiogenesis and progression by upregulating Wnt-inducible signaling pathway protein 3 (WISP3) and activating Wnt signaling. This study aims to explore WISP3's role and mechanisms in NSCLC progression. Cells were transfected with a reconstructed plasmid to study gene overexpression/silencing effects. Functional assays were conducted, including tube formation, sphere formation, immunohistochemistry, western blotting, Transwell, and MTT. Mass spectrometry and bioinformatics analysis were used to identify differentially expressed proteins and their associated signaling pathways in NSCLC cells. Additionally, the xenograft tumor model of NSCLC was constructed. High expression of WISP3 in NSCLC is associated with poor prognosis, as it enhances angiogenic and tumorigenic potential in NSCLC cells, further verified in our constructed xenograft tumor experiment. In terms of mechanisms, the activation of the TGF-β signaling pathway, indicated by p-smad2/3 activation, is implicated in the progression of NSCLC promoted by WISP3. Additionally, overexpression of WISP3 leads to increased syntenin binding protein (SDCBP) expression in vitro and in vivo, and WISP3 binding to SDCBP enhances angiogenic and tumorigenic potential in NSCLC, which can be counteracted by silencing SDCBP, indicating their crucial role in NSCLC progression. We offer new insights into WISP3's role in promoting NSCLC progression, showing it upregulates SDCBP and is involved in TGF-β signaling. The findings contribute to a better understanding of NSCLC biology and suggest potential therapeutic targets for the disease.

9 June 2026 in Cancer Cell International
Verified
Journal Article
Open access
FZFei Zhou
Fei Zhou
GFGaohua Feng
Gaohua Feng
XZXiaoshen Zhang
Xiaoshen Zhang
CZChangbin Zhu
Changbin Zhu
TJTao Jiang
Tao Jiang
GGGuanghui Gao
Guanghui Gao
Targeting immune checkpoints, specifically programmed death 1, has significantly improved clinical outcomes in non-small cell lung cancer. However, only a proportion of patients benefited from immune checkpoint blockades (ICBs) therapy. Thus, identifying novel biomarkers to better select responders to ICBs is critically important in clinical practice. This retrospective study included two cohorts, a discovery cohort (n = 24) and a validation cohort (n = 21) of lung adenocarcinoma (LUAD) patients treated with ICB at Shanghai Pulmonary Hospital between April 2016 and November 2019. Formalin-fixed paraffin-embedded tissue samples were collected for RNA sequencing. Additionally, a TCGA dataset (GSE135222) and a clinical study dataset (POPLAR) were utilized as external validation and test sets, respectively. In the discovery cohort, cilia-associated pathways were significantly enriched in LUAD patients with non-durable benefit. A three-gene cilia-associated signature (TMEM100, DNAH3, and NEFH) was established and effectively predicted resistance to ICB treatment (discovery cohort, Hazard Ratio [HR, 95% CI] = 0.21 [0.056-0.791], P = 3.64e-05; validation cohort, HR [95% CI] = 0.200 [0.049-0.830], P = 0.0003). This signature was further validated in an external cohort (HR [95% CI] = 0.461 [ 0.164-1.292], P = 0.067). Further analysis demonstrated that the cilia-associated signature was negatively associated with various types of tumor-infiltrating immune cells, including effector T cells, macrophages, and dendritic cells. Our findings suggest that cilia-associated signature may serve as a potential biomarker to identify LUAD patients with reduced likelihood of benefiting from ICB therapy, though further validation in larger cohorts is warranted.